文献速递流行病学与生物统计真实世界研究与卫生经济

SGLT2抑制剂与COVID-19结局观察性研究的系统综述:方法学评价

A systematic review of observational studies of sodium-glucose cotransporter 2 inhibitors and COVID-19 outcomes: a methodological assessment.
PubMed 文献 · J Clin Epidemiol · 2026-05-26

该系统综述纳入20项队列研究,评估2型糖尿病合并COVID-19患者使用SGLT2抑制剂与死亡和住院风险的关联。5项研究报告全因死亡风险降低(效应估计范围0.25-0.82),4项报告住院风险降低(范围0.79-0.92),但14项存在严重偏倚风险、6项为极严重风险,方法学问题限制了结论可靠性。

要点

  • SGLT2抑制剂与COVID-19结局的观察性研究普遍存在严重偏倚风险。
  • 部分研究报告死亡和住院风险降低,但异质性大且未行荟萃分析。
  • 公共卫生紧急事件中仍需坚持方法学严谨性以生成可靠证据。

核心结论

  • 现有观察性研究方法学问题突出,限制了SGLT2抑制剂在2型糖尿病合并COVID-19患者中有效性的结论推断。

研究设计与样本

  • 系统综述检索Embase、MEDLINE和WHO COVID-19研究文献库至2025年3月,纳入报告死亡或住院风险的观察性研究,使用ROBINS-I工具评价质量。

主要发现

  • 共纳入20项队列研究,18项报告全因死亡,8项报告COVID-19相关住院。
  • 5项研究报告全因死亡风险降低,效应估计范围0.25至0.82。
  • 4项研究报告住院风险降低,范围0.79至0.92;其余研究报告无关联。
  • 14项研究存在严重偏倚风险,6项为极严重风险。
  • 因研究质量低且异质性大,未进行荟萃分析。

临床怎么用

  • 解读此类观察性证据时应谨慎,不宜直接用于临床决策。
  • 未来研究需重点控制混杂、规范暴露与结局评估。

局限性

  • 纳入研究质量低且异质性大,无法进行定量合并。
  • 方法学问题涉及对象选择、混杂控制不足及暴露与结局评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To conduct a systematic review of observational studies examining the association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and the risk of mortality and of hospitalization compared with the use of other antidiabetic medications in patients with type two diabetes and COVID-19, with a focus on the methodological quality. We also describe how such studies can be improved when addressing a public health emergency. STUDY DESIGN AND SETTING: We conducted a systematic review by searching Embase, MEDLINE, and the WHO COVID-19 research article databases up to March 2025. Observational studies reporting on the risk of mortality and of hospitalization with the use of SGLT2 inhibitors among patients with type two diabetes and COVID-19 were included and study quality was assessed using the ROBINS-I tool. Our systematic review focused on the methodological assessment of the literature. RESULTS: We included 20 cohort studies, with 18 reporting on all-cause mortality and eight on COVID-19-related hospitalization. Five studies reported a decreased risk of all-cause mortality (range of effects estimates: 0.25 to 0.82), compared with nonuse or use of other drugs, and four studies reported a decreased risk of hospitalization (range: 0.79 to 0.92); the others reported no association. Overall, 14 studies were at serious risk of bias and six were at critical risk. We identified several methodological issues related to the selection of participants, inadequate control of confounding, and assessment of exposure and outcomes. No meta-analysis was conducted due to the low quality and heterogeneity of the included studies. CONCLUSIONS: The observational studies examining the effectiveness of SGLT2 inhibitors among patients with type two diabetes and COVID-19 outcomes have important methodological issues that limit the conclusions that can be drawn from this knowledge base. Although public health emergencies require rapid responses, methodological rigor remains essential to generate actionable evidence.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. St-Jean A, Moriello C, Yu OHY, et al. A systematic review of observational studies of sodium-glucose cotransporter 2 inhibitors and COVID-19 outcomes: a methodological assessment. J Clin Epidemiol. 2026. PMID: 42203176. doi:10.1016/j.jclinepi.2026.112347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。